Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review
@article{Deleu2000CurrentAE, title={Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review}, author={D. Deleu and Y. Hanssens}, journal={The Journal of Clinical Pharmacology}, year={2000}, volume={40} }
Sterile neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a pathophysiological mechanism in acute migraine. The action of 5‐hydroxytryptamine (5‐HT1B/1D) agonists—so‐called triptans—on receptors located in meningeal arteries (5‐HT1B) and trigeminovascular fiber endings (5‐HT1D) has an inhibitory effect on this neurogenic inflammation. Recently, a series of second‐generation 5‐HT1B/1D agonists (almotriptan, eletriptan… CONTINUE READING
Topics from this paper
83 Citations
Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
- Medicine
- Pharmacology & therapeutics
- 2018
- 33
- PDF
Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.
- Medicine
- Progress in brain research
- 2020
Therapies in development for the treatment of migraine
- Medicine
- Expert opinion on investigational drugs
- 2002
- 3
Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence‐based pharmacotherapeutic case report
- Medicine
- Journal of clinical pharmacy and therapeutics
- 2003
- 2
- PDF
Renal Infarction During the Use of Rizatriptan and Zolmitriptan: Two Case Reports
- Medicine
- Clinical toxicology
- 2006
- 17
References
SHOWING 1-10 OF 165 REFERENCES
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
- Chemistry, Medicine
- British journal of pharmacology
- 1997
- 98
Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study
- Medicine
- European journal of neurology
- 1998
- 54
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
- Medicine
- Acta neurologica Belgica
- 1999
- 10
Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
- Medicine
- Cephalalgia : an international journal of headache
- 1997
- 71
Rizatriptan has central antinociceptive effects against durally evoked responses.
- Chemistry, Medicine
- European journal of pharmacology
- 1997
- 146
Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors
- Medicine
- British journal of pharmacology
- 1997
- 104
5‐HT1 receptors in migraine pathophysiology and treatment
- Medicine
- European journal of neurology
- 1995
- 80